Of all vaccines in use in the world, Sinovac is the one with the least impressive and most inconsistent results. A Brazilian study in January suggested that it had an efficacy rate in preventing symptomatic illness of 50.4 per cent, way below the 95 per cent reported for Pfizer and 76 per cent measured for AstraZeneca in its recent US trial.
